Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × HER2-positive Breast Cancer × Capecitabine × Clear all

Phase

Phase 2 2 Phase 4 1 Phase 3 1 Phase 2/3 1

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 13 Colorectal Neoplasms 6 Stomach Neoplasms 5 Neoplasm Metastasis 4 Biliary Tract Neoplasms 4 Pancreatic Neoplasms 3 Neoplasms 3 Esophageal Neoplasms 3 Carcinoma, Hepatocellular 3 Rectal Neoplasms 2 Colonic Neoplasms 2 Adenocarcinoma Of Esophagus 2 Resected Liver Metastases From Colorectal Cancer 1 Recurrence 1 Quality of Life 1 Oesophagogastric Cancer 1 Inflammatory Breast Neoplasms 1 HER2-positive Gastric Cancer 1 HER2-positive Breast Cancer 1 Gastroesophageal Junction Adenocarcinoma 1 Gallbladder Neoplasms 1 Esophageal Squamous Cell Carcinoma 1 Cholangiocarcinoma 1 Breast Diseases 1 Bile Duct Neoplasms 1 Anus Neoplasms 1 Adenocarcinoma 1

Interventions

Trastuzumab 3 pertuzumab 2 Docetaxel 2 tucatinib 1 Protons 1 Paclitaxel 1 Carboplatin 1 Capecitabine 1 ARX788 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07413939 2026-03-10

BREnnA

Hoffmann-La Roche

Phase 2/3 Not yet recruiting

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡